Omega Healthcare Investors (OHI) Price to Sales (2009 - 2026)

Omega Healthcare Investors has disclosed Price to Sales across 17 years of filings, most recently posting 43.45 for Q2 2026.

• In Q2 2026, Price to Sales rose 14.24% year-over-year to 43.45; the TTM figure through Jun 2026 stood at 11.12 (up 15.41% YoY), while the FY2025 annual figure was 11.01, up 9.58% from the prior year.
• Price to Sales came in at 43.45 for Q2 2026 at Omega Healthcare Investors, up from 40.41 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 45.2 in Q4 2022 to a low of 26.97 in Q2 2022.
• Average Price to Sales over 5 years is 35.61, with a median of 36.12 recorded in 2024.
• Year-over-year, Price to Sales plunged 94.44% in 2022 and rose 22.79% in 2025.
• Over 5 years, Price to Sales stood at 45.2 in 2022, then plunged by 30.48% to 31.42 in 2023, then climbed by 20.37% to 37.82 in 2024, then climbed by 8.53% to 41.05 in 2025, then gained by 5.84% to 43.45 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 43.45 in Q2 2026, 40.41 in Q1 2026, and 41.05 in Q4 2025.